Development of lacosamide for the treatment of partial‐onset seizures
Identifieur interne : 000701 ( Main/Exploration ); précédent : 000700; suivant : 000702Development of lacosamide for the treatment of partial‐onset seizures
Auteurs : Pamela Doty ; David Hebert ; Francois-Xavier Mathy [Belgique] ; William Byrnes ; James Zackheim [Géorgie (pays)] ; Kelly Simontacchi [Géorgie (pays)]Source :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2013-07.
Abstract
Lacosamide is an antiepileptic drug (AED) available in multiple formulations that was first approved in 2008 as adjunctive therapy for partial‐onset seizures (POS) in adults. Unlike traditional sodium channel blockers affecting fast inactivation, lacosamide selectively enhances sodium channel slow inactivation. This mechanism of action results in stabilization of hyperexcitable neuronal membranes, inhibition of neuronal firing, and reduction in long‐term channel availability without affecting physiological function. Lacosamide has a well‐characterized and favorable pharmacokinetic profile, including a fast absorption rate, minimal or no interaction with cytochrome P‐450 izoenzymes, and a low potential for drug–drug interactions. Lacosamide clinical development included three placebo‐controlled, double‐blind, randomized trials conducted in more than 1300 patients, each demonstrating safety and efficacy of lacosamide compared to placebo as adjunctive therapy for adults with POS. The clinical use of lacosamide may broaden, pending results of trials evaluating its use as monotherapy for POS in adults, as treatment for epilepsy in pediatric subjects, and as adjunctive treatment for uncontrolled primary generalized tonic–clonic seizures in those with idiopathic generalized epilepsy.
Url:
DOI: 10.1111/nyas.12213
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001276
- to stream Istex, to step Curation: 001252
- to stream Istex, to step Checkpoint: 000358
- to stream Main, to step Merge: 000702
- to stream Main, to step Curation: 000701
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of lacosamide for the treatment of partial‐onset seizures</title><author><name sortKey="Doty, Pamela" sort="Doty, Pamela" uniqKey="Doty P" first="Pamela" last="Doty">Pamela Doty</name></author><author><name sortKey="Hebert, David" sort="Hebert, David" uniqKey="Hebert D" first="David" last="Hebert">David Hebert</name></author><author><name sortKey="Mathy, Francois Avier" sort="Mathy, Francois Avier" uniqKey="Mathy F" first="Francois-Xavier" last="Mathy">Francois-Xavier Mathy</name></author><author><name sortKey="Byrnes, William" sort="Byrnes, William" uniqKey="Byrnes W" first="William" last="Byrnes">William Byrnes</name></author><author><name sortKey="Zackheim, James" sort="Zackheim, James" uniqKey="Zackheim J" first="James" last="Zackheim">James Zackheim</name></author><author><name sortKey="Simontacchi, Kelly" sort="Simontacchi, Kelly" uniqKey="Simontacchi K" first="Kelly" last="Simontacchi">Kelly Simontacchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:39E121577FBE75742003C074D674CEF66AC13F48</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/nyas.12213</idno><idno type="url">https://api.istex.fr/document/39E121577FBE75742003C074D674CEF66AC13F48/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001276</idno><idno type="wicri:Area/Istex/Curation">001252</idno><idno type="wicri:Area/Istex/Checkpoint">000358</idno><idno type="wicri:doubleKey">0077-8923:2013:Doty P:development:of:lacosamide</idno><idno type="wicri:Area/Main/Merge">000702</idno><idno type="wicri:Area/Main/Curation">000701</idno><idno type="wicri:Area/Main/Exploration">000701</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development of lacosamide for the treatment of partial‐onset seizures</title><author><name sortKey="Doty, Pamela" sort="Doty, Pamela" uniqKey="Doty P" first="Pamela" last="Doty">Pamela Doty</name><affiliation><wicri:noCountry code="subField">Raleigh</wicri:noCountry></affiliation></author><author><name sortKey="Hebert, David" sort="Hebert, David" uniqKey="Hebert D" first="David" last="Hebert">David Hebert</name><affiliation><wicri:noCountry code="subField">Raleigh</wicri:noCountry></affiliation></author><author><name sortKey="Mathy, Francois Avier" sort="Mathy, Francois Avier" uniqKey="Mathy F" first="Francois-Xavier" last="Mathy">Francois-Xavier Mathy</name><affiliation wicri:level="3"><country xml:lang="fr">Belgique</country><wicri:regionArea>UCB Pharma, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Byrnes, William" sort="Byrnes, William" uniqKey="Byrnes W" first="William" last="Byrnes">William Byrnes</name><affiliation><wicri:noCountry code="subField">Raleigh</wicri:noCountry></affiliation></author><author><name sortKey="Zackheim, James" sort="Zackheim, James" uniqKey="Zackheim J" first="James" last="Zackheim">James Zackheim</name><affiliation wicri:level="1"><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>UCB Pharma, Smyrna</wicri:regionArea><wicri:noRegion>Smyrna</wicri:noRegion></affiliation></author><author><name sortKey="Simontacchi, Kelly" sort="Simontacchi, Kelly" uniqKey="Simontacchi K" first="Kelly" last="Simontacchi">Kelly Simontacchi</name><affiliation wicri:level="1"><country xml:lang="fr">Géorgie (pays)</country><wicri:regionArea>UCB Pharma, Smyrna</wicri:regionArea><wicri:noRegion>Smyrna</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the New York Academy of Sciences</title><title level="j" type="abbrev">Ann. N.Y. Acad. Sci.</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-07">2013-07</date><biblScope unit="volume">1291</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="56">56</biblScope><biblScope unit="page" to="68">68</biblScope></imprint><idno type="ISSN">0077-8923</idno></series><idno type="istex">39E121577FBE75742003C074D674CEF66AC13F48</idno><idno type="DOI">10.1111/nyas.12213</idno><idno type="ArticleID">NYAS12213</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Lacosamide is an antiepileptic drug (AED) available in multiple formulations that was first approved in 2008 as adjunctive therapy for partial‐onset seizures (POS) in adults. Unlike traditional sodium channel blockers affecting fast inactivation, lacosamide selectively enhances sodium channel slow inactivation. This mechanism of action results in stabilization of hyperexcitable neuronal membranes, inhibition of neuronal firing, and reduction in long‐term channel availability without affecting physiological function. Lacosamide has a well‐characterized and favorable pharmacokinetic profile, including a fast absorption rate, minimal or no interaction with cytochrome P‐450 izoenzymes, and a low potential for drug–drug interactions. Lacosamide clinical development included three placebo‐controlled, double‐blind, randomized trials conducted in more than 1300 patients, each demonstrating safety and efficacy of lacosamide compared to placebo as adjunctive therapy for adults with POS. The clinical use of lacosamide may broaden, pending results of trials evaluating its use as monotherapy for POS in adults, as treatment for epilepsy in pediatric subjects, and as adjunctive treatment for uncontrolled primary generalized tonic–clonic seizures in those with idiopathic generalized epilepsy.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>Géorgie (pays)</li></country><region><li>Région de Bruxelles-Capitale</li></region><settlement><li>Bruxelles</li></settlement></list><tree><noCountry><name sortKey="Byrnes, William" sort="Byrnes, William" uniqKey="Byrnes W" first="William" last="Byrnes">William Byrnes</name><name sortKey="Doty, Pamela" sort="Doty, Pamela" uniqKey="Doty P" first="Pamela" last="Doty">Pamela Doty</name><name sortKey="Hebert, David" sort="Hebert, David" uniqKey="Hebert D" first="David" last="Hebert">David Hebert</name></noCountry><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Mathy, Francois Avier" sort="Mathy, Francois Avier" uniqKey="Mathy F" first="Francois-Xavier" last="Mathy">Francois-Xavier Mathy</name></region></country><country name="Géorgie (pays)"><noRegion><name sortKey="Zackheim, James" sort="Zackheim, James" uniqKey="Zackheim J" first="James" last="Zackheim">James Zackheim</name></noRegion><name sortKey="Simontacchi, Kelly" sort="Simontacchi, Kelly" uniqKey="Simontacchi K" first="Kelly" last="Simontacchi">Kelly Simontacchi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000701 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000701 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:39E121577FBE75742003C074D674CEF66AC13F48
|texte= Development of lacosamide for the treatment of partial‐onset seizures
}}
| This area was generated with Dilib version V0.6.25. |  |